ES2146307T3 - Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa. - Google Patents

Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa.

Info

Publication number
ES2146307T3
ES2146307T3 ES95904328T ES95904328T ES2146307T3 ES 2146307 T3 ES2146307 T3 ES 2146307T3 ES 95904328 T ES95904328 T ES 95904328T ES 95904328 T ES95904328 T ES 95904328T ES 2146307 T3 ES2146307 T3 ES 2146307T3
Authority
ES
Spain
Prior art keywords
unsubstituted
compounds
imidazolinylamine
alkanyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904328T
Other languages
English (en)
Inventor
Thomas Lee Cupps
Peter Julian Maurer
Jeff Ares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/326,564 external-priority patent/US5578607A/en
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Application granted granted Critical
Publication of ES2146307T3 publication Critical patent/ES2146307T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE COMPUESTOS QUE TIENEN LA ESTRUCTURA (I) EN DONDE: (A) R ES ALCANILO O ALQUENILO INSUSTITUIDO DE C{SUB,1}-C{SUB,3}; R'' SE SELECCIONA ENTRE ALQUENILO O ALQUINILO DE C{SUB,1}-C{SUB,3} INSUSTITUIDO; ALQUILTIO O ALCOXI INSUSTITUIDO DE C{SUB,1}-C{SUB,3}; HIDROXI; TIOL; Y HALOGENO; Y (C) R" SE SELECCIONA ENTRE HIDROGENO, ALCANILO O ALQUENILO INSUSTITUIDO DE C{SUB,1}-C{SUB,3}, METILO MONOSUSTIUIDO CON HIDROXI, TIOL O AMINO; ALQUILTIO O ALCOXI INSUSTITUIDO DE C{SUB,1}-C{SUB,3}; AMINO; AMIDA INSUSTITUIDA; AMIDA INSUSTITUIDA O SUSTITUIDA CON C{SUB,1}-C{SUB,3}, HALOGENO; SULFOXIDO INSUSTITUIDO; SULFONILO INSUSTITUIDO Y CIANO; COMPOSICIONES FARMACEUTICAS QUE LLEVAN ESTOS COMPUESTOS, Y LA UTILIZACION DE TALES COMPUESTOS PARA PREVENIR O TRATAR TRANSTORNOS RESPIRATORIOS, OCULARES Y/O GASTROINTESTINALES.
ES95904328T 1993-12-17 1994-12-15 Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa. Expired - Lifetime ES2146307T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16934393A 1993-12-17 1993-12-17
US08/326,564 US5578607A (en) 1993-12-17 1994-10-20 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
ES2146307T3 true ES2146307T3 (es) 2000-08-01

Family

ID=26864975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904328T Expired - Lifetime ES2146307T3 (es) 1993-12-17 1994-12-15 Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa.

Country Status (23)

Country Link
US (1) US5739148A (es)
EP (1) EP0736020B1 (es)
JP (1) JPH09511483A (es)
CN (1) CN1046718C (es)
AT (1) ATE192150T1 (es)
AU (1) AU699041B2 (es)
BR (1) BR9408335A (es)
CA (1) CA2179264C (es)
CZ (1) CZ285481B6 (es)
DE (1) DE69424183T2 (es)
DK (1) DK0736020T3 (es)
ES (1) ES2146307T3 (es)
FI (1) FI962491A (es)
GR (1) GR3033515T3 (es)
HK (1) HK1013072A1 (es)
HU (1) HU217841B (es)
NO (1) NO308662B1 (es)
NZ (1) NZ333370A (es)
PL (1) PL180392B1 (es)
PT (1) PT736020E (es)
SG (1) SG55141A1 (es)
SK (1) SK77096A3 (es)
WO (1) WO1995016683A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
DK1742642T3 (da) * 2004-04-14 2009-02-16 Gilead Sciences Inc Phosphonatanaloge af HIV-integraseinhibitorforbindelser
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
JP6031719B2 (ja) 2011-07-25 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ２アドレナリン作動性受容体のモジュレーターとしてのｎ−（イミダゾリジン−２−イリデン）キノリン誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) * 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
DE3071229D1 (en) * 1979-08-23 1985-12-19 Beecham Group Plc Anti-diarrhoea veterinary composition
EP0047328B1 (de) * 1980-09-05 1984-05-09 Siegfried Aktiengesellschaft 1H- und 2H-Indazolderivate und diese enthaltendes Arzneimittel
FR2638356A1 (fr) * 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
PL180392B1 (pl) 2001-01-31
ATE192150T1 (de) 2000-05-15
PL315060A1 (en) 1996-09-30
FI962491A0 (fi) 1996-06-14
HU217841B (hu) 2000-04-28
JPH09511483A (ja) 1997-11-18
CN1137793A (zh) 1996-12-11
NZ333370A (en) 2001-03-30
CA2179264C (en) 1999-05-18
EP0736020B1 (en) 2000-04-26
AU1306395A (en) 1995-07-03
HU9601659D0 (en) 1996-08-28
NO962536L (no) 1996-08-02
CA2179264A1 (en) 1995-06-22
CN1046718C (zh) 1999-11-24
GR3033515T3 (en) 2000-09-29
FI962491A (fi) 1996-07-26
HUT76277A (en) 1997-07-28
AU699041B2 (en) 1998-11-19
HK1013072A1 (en) 1999-08-13
CZ285481B6 (cs) 1999-08-11
WO1995016683A1 (en) 1995-06-22
NO308662B1 (no) 2000-10-09
DE69424183T2 (de) 2001-02-15
BR9408335A (pt) 1997-08-19
US5739148A (en) 1998-04-14
CZ175396A3 (en) 1996-11-13
SK77096A3 (en) 1997-02-05
DE69424183D1 (de) 2000-05-31
PT736020E (pt) 2000-10-31
EP0736020A1 (en) 1996-10-09
DK0736020T3 (da) 2000-08-07
SG55141A1 (en) 1998-12-21
NO962536D0 (no) 1996-06-14

Similar Documents

Publication Publication Date Title
NO962539L (no) 5-(2-imidazolinylamino)benzimidazol-derivater, deres fremstilling og deres anvendelse som -2-adreniceptor-agonister
ES2146307T3 (es) Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa.
EA200200208A1 (ru) Синергитическая композиция
FI962493A (fi) Alfa-2-adrenoseptoriagonisteina käyttökelpoisia 6-(2-imidatsolinyyliamino)kinoksaliiniyhdisteitä
ES2158076T3 (es) Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores.
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
KR950002761A (ko) 강박 반응 장애 치료제 제조용으로서의 n-(피리디닐)-1h-인돌-1-아민의 용도
KR910000150A (ko) 대사성 골 질환 치료제
BR0209065A (pt) Sulfato de composto de cefemo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 736020

Country of ref document: ES